FibroBiologics Sets Another Record as Highest Amount Raised per Biotech Investor in StartEngine.com History

HOUSTON, February 24, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced they have raised the highest amount per biotech investor in StartEngine history surpassing $6,900/investor as an average investment size. StartEngine is one of the largest equity crowdfunding platforms in the U.S., led by […]

FibroBiologics Sets Record as Fastest Rising Biotech in History with StartEngine.com

HOUSTON, February 1, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced they are the fastest rising biotech offering in StartEngine’s history surpassing $1 million of new investments on the first day of its Reg CF offering. StartEngine is one of the largest equity crowdfunding […]

FibroBiologics Launches Public Funding Campaign with StartEngine.com

HOUSTON, January 31, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today launched an online funding campaign with StartEngine, a leading equity crowdfunding platform. Regulation Crowdfunding allows everyone to invest in securities issued by startup companies, regardless of their net worth or income level. The funding […]